Servier’s new treatment approved for coronary artery disease

Servier's pipeline drug Procoralan (ivabradine), the first pure heart rate-lowering agent, has recently received an approval from the Korea Food and Drug Administration for the treatment of chronic stable angina in patients with normal sinus rhythm who have a contraindication or intolerance to beta-blockers.

Heart rate reduction has been a therapeutic goal in angina treatment for many years...